
Madrigal Pharmaceuticals, Inc.: updates and filings
Price
$398.08
November 18, 2026Market cap $11.6B
What Ploutos Investor adds for Madrigal Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 10 fiscal years, from 2012
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 3, 2026next Feb 3, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
July 2026
May 2026
February 2026
January 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 6, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Nov 3, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 3, 2026Results of operationsForm8-K
- Aug 12, 2026Officer or director change, Regulation FD disclosureForm8-K
- Jul 30, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jul 30, 2026Results of operationsForm8-K
- Jul 29, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jun 17, 2026Shares registered for employeesFormS-8
- Jun 17, 2026Officer or director change, shareholder voteForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 6, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 6, 2026Results of operationsForm8-K
- Apr 28, 2026Officer or director changeForm8-K
- Apr 28, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 28, 2026Additional annual meeting materialFormDEFA14A
- Apr 28, 2026Annual meeting proxy statementFormDEF 14A
- Mar 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Feb 19, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 19, 2026Results of operationsForm8-K
- Feb 17, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Feb 17, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jan 30, 2026Material agreement enteredForm8-K
- Dec 12, 2025Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 6, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Nov 3, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 3, 2026 | 8-K | Results of operations | Document |
| Aug 12, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| Jul 30, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jul 30, 2026 | 8-K | Results of operations | Document |
| Jul 29, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jun 17, 2026 | S-8 | Shares registered for employees | Document |
| Jun 17, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 6, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 6, 2026 | 8-K | Results of operations | Document |
| Apr 28, 2026 | 8-K | Officer or director change | Document |
| Apr 28, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 28, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 28, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Feb 19, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 19, 2026 | 8-K | Results of operations | Document |
| Feb 17, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Feb 17, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jan 30, 2026 | 8-K | Material agreement entered | Document |
| Dec 12, 2025 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since May 31, 2002.
The full analysis
What do Madrigal Pharmaceuticals's filings show?
The filings are where every one of Madrigal Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.